Thompson J, Schneider P, Kalled S, Wang L, Lefevre E, Cachero T, et al. BAFF binds to the tumor necrosis factor receptor-like molecule B cell maturation antigen and is important for maintaining the peripheral B cell population. J Exp Med. 2000;192:129–35.
Article
PubMed Central
CAS
PubMed
Google Scholar
Do R, Hatada E, Lee H, Tourigny M, Hilbert D, Chen-Kiang S. Attenuation of apoptosis underlies B lymphocyte stimulator enhancement of humoral immune response. J Exp Med. 2000;192:953–64.
Article
PubMed Central
CAS
PubMed
Google Scholar
Batten M, Groom J, Cachero T, Qian F, Schneider P, Tschopp J, et al. BAFF mediates survival of peripheral immature B lymphocytes. J Exp Med. 2000;192:1453–66.
Article
PubMed Central
CAS
PubMed
Google Scholar
Gross J, Dillon S, Mudri S, Johnston J, Littau A, Roque R, et al. TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease impaired B cell maturation in mice lacking BLyS. Immunity. 2001;15:289–302.
Article
CAS
PubMed
Google Scholar
Schiemann B, Gommerman J, Vora K, Cachero T, Shulga-Morskaya S, Dobles M, et al. An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway. Science. 2001;293:2111–4.
Article
CAS
PubMed
Google Scholar
Mackay F, Woodcock S, Lawton P, Ambrose C, Baetscher M, Schneider P, et al. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med. 1999;190:1697–710.
Article
PubMed Central
CAS
PubMed
Google Scholar
Khare S, Sarosi I, Xia X, McCabe S, Minder K, Solovyev I, et al. Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice. PNAS. 2000;97:3370–5.
Article
PubMed Central
CAS
PubMed
Google Scholar
Gross J, Johnston J, Mudri S, Enselman R, Dillon S, Madden K, et al. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature. 2000;404:995–9.
Article
CAS
PubMed
Google Scholar
Stohl W, Xu D, Kim K, Koss M, Jorgensen T, Deocharan B, et al. BAFF overexpression and accelerated glomerular disease in mice with incomplete genetic predisposition to systemic lupus erythematosus. Arthritis Rheum. 2005;52:2080–91.
Article
CAS
PubMed
Google Scholar
Groom J, Fletcher C, Walters S, Grey S, Watt S, Sweet M, et al. BAFF and MyD88 signals promote a lupus-like disease independent of T cells. J Exp Med. 2007;204:1959–71.
Article
PubMed Central
CAS
PubMed
Google Scholar
Kayagaki N, Yan M, Seshasayee D, Wang H, Lee W, French D, et al. BAFF/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a discrete surface loop and promotes processing of NF-kappaB2. Immunity. 2002;17:515–24.
Article
CAS
PubMed
Google Scholar
Ramanujam M, Wang X, Huang W, Liu Z, Schiffer L, Tao H, et al. Similarities and differences between selective and nonselective BAFF blockade in murine SLE. J Clin Invest. 2006;116:724–34.
Article
PubMed Central
CAS
PubMed
Google Scholar
Jacob C, Pricop L, Putterman C, Koss M, Liu Y, Kollaros M, et al. Paucity of clinical disease despite serological autoimmunity and kidney pathology in lupus-prone New Zealand mixed 2328 mice deficient in BAFF. J Immunol. 2006;177:2671–80.
Article
PubMed Central
CAS
PubMed
Google Scholar
Zhang J, Roschke V, Baker K, Wang Z, Alarcón G, Fessler B, et al. Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus. J Immunol. 2001;166:6–10.
Article
CAS
PubMed
Google Scholar
Cheema G, Roschke V, Hilbert D, Stohl W. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum. 2001;44:1313–9.
Article
CAS
PubMed
Google Scholar
Stohl W, Metyas S, Tan S, Cheema G, Oamar B, Xu D, et al. B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations. Arthritis Rheum. 2003;48:3475–86.
Article
PubMed
Google Scholar
Petri M, Stohl W, Chatham W, McCune W, Chevrier M, Ryel J, et al. Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. Arthritis Rheum. 2008;58:2453–9.
Article
CAS
PubMed
Google Scholar
Collins C, Gavin A, Migone T, Hilbert D, Nemazee D, Stohl W. B lymphocyte stimulator (BLyS) isoforms in systemic lupus erythematosus: disease activity correlates better with blood leukocyte BLyS mRNA levels than with plasma BLyS protein levels. Arthritis Res Ther. 2006;8:R6.
Article
PubMed Central
PubMed
Google Scholar
Becker-Merok A, Nikolaisen C, Nossent H. B-lymphocyte activating factor in systemic lupus erythematosus and rheumatoid arthritis in relation to autoantibody levels, disease measures and time. Lupus. 2006;15:570–6.
Article
CAS
PubMed
Google Scholar
Ju S, Zhang D, Wang Y, Ni H, Kong X, Zhong R. Correlation of the expression levels of BLyS and its receptors mRNA in patients with systemic lupus erythematosus. Clin Biochem. 2006;39:1131–7.
Article
CAS
PubMed
Google Scholar
Hong S, Reiff A, Yang H, Migone T, Ward C, Marzan K, et al. B lymphocyte stimulator expression in pediatric systemic lupus erythematosus and juvenile idiopathic arthritis patients. Arthritis Rheum. 2009;60:3400–9.
Article
CAS
PubMed
Google Scholar
Navarra S, Guzmán R, Gallacher A, Hall S, Levy R, Jimenez R, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377:721–31.
Article
CAS
PubMed
Google Scholar
Furie R, Petri M, Zamani O, Cervera R, Wallace D, Tegzová D, et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011;63:3918–30.
Article
CAS
PubMed
Google Scholar
Hsu H, Khare S, Lee F, Miner K, Hu Y, Stolina M, et al. A novel modality of BAFF-specific inhibitor AMG623 peptibody reduces B-cell number and improves outcomes in murine models of autoimmune disease. Clin Exp Rheumatol. 2012;30:197–201.
PubMed
Google Scholar
Tan E, Cohen A, Fries J, Masi A, McShane D, Rothfield N, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25:1271–7.
Article
CAS
PubMed
Google Scholar
Hochberg M. Updating the American College of Rheumatology revised criteria for the classification of systemic erythematosus lupus. Arthritis Rheum. 1997;40:1725–34.
Article
CAS
PubMed
Google Scholar
Belouski S, Wallace D, Weisman M, Ishimori M, Hendricks L, Zack D, et al. Sample stability and variability of B-cell subsets in blood from healthy subjects and patients with systemic lupus erythematosus. Cytometry B Clin Cytom. 2010;78:49–58.
PubMed
Google Scholar
Reinsch C. Smoothing by spline functions. Numer Math. 1967;10:177–83.
Article
Google Scholar
Dall’Era M, Chakravarty E, Wallace D, Genovese M, Weisman M, Kavanaugh A, et al. Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial. Arthritis Rheum. 2007;56:4142–50.
Article
PubMed
Google Scholar
Tak P, Thurlings R, Rossier C, Nestorov I, Dimic A, Mircetic V, et al. Atacicept in patients with rheumatoid arthritis: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating, single- and repeated-dose study. Arthritis Rheum. 2008;58:61–72.
Article
CAS
PubMed
Google Scholar
Wallace D, Stohl W, Furie R, Lisse J, McKay J, Merrill J, et al. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum. 2009;61:1168–78.
Article
PubMed Central
CAS
PubMed
Google Scholar
Stohl W, Hiepe F, Latinis K, Thomas M, Scheinberg M, Clarke A, et al. Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus. Arthritis Rheum. 2012;64:2328–37.
Article
PubMed Central
CAS
PubMed
Google Scholar
Looney R, Anolik J, Campbell D, Felgar R, Young F, Arend L, et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum. 2004;50:2580–9.
Article
CAS
PubMed
Google Scholar
Sato S, Hasegawa M, Fujimoto M, Tedder TF, Takehara K. Quantitative genetic variation in CD19 expression correlates with autoimmunity. J Immunol. 2000;165:6635–43.
Article
CAS
PubMed
Google Scholar
Korganow AS, Knapp AM, Nehme-Schuster H, Soulas-Sprauel P, Poindron V, Pasquali JL, et al. Peripheral B cell abnormalities in patients with systemic lupus erythematosus in quiescent phase: decreased memory B cells and membrane CD19 expression. J Autoimmun. 2010;34:426–3.
Article
CAS
PubMed
Google Scholar
Merrill JT, Neuwelt CM, Wallace DJ, Shanahan JC, Latinis KM, Oates JC, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 2008;62:222–33.
Article
Google Scholar
Rovin BH, Furie R, Latinis K, Looney RJ, Fervenza FC, Sanchez-Guerrero J, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum. 2012;64:1215–26.
Article
CAS
PubMed
Google Scholar
Pena-Rossi C, Nasonov E, Stanislav M, Yakusevich V, Ershova O, Lomareva N, et al. An exploratory dose-escalating study investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of intravenous atacicept in patients with systemic lupus erythematosus. Lupus. 2009;18:547–55.
Article
PubMed Central
CAS
PubMed
Google Scholar
Baker KP, Edwards BM, Main SH, Choi GH, Wager RE, Halpern WG, et al. Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum. 2003;48:3253–65.
Article
CAS
PubMed
Google Scholar
Furie RA, Scheinberg MA, Leon G, Ramiterre EB, Thomas M, Martin RS, et al. A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study. Ann Rheum Dis 2014. doi: 10.1136/annrheumdis-2013-205144. Epub ahead of print.
Isenberg DA, Urowitz MB, Merrill JT, Hoffman RW, Linnik MD, Morgan-Cox M, et al. Efficacy and Safety of subcutaneous tabalumab in patients with systemic lupus erythematosus (SLE): Results from 2 phase 3, 52-week, multicenter, randomized, double-blind, placebo-controlled trials. Arthritis Rheum. 2014;66:S225.
Google Scholar
Bossen C, Tardivel A, Willen L, Fletcher C, Perroud M, Beermann F, et al. Mutation of the BAFF furin cleavage site impairs B-cell homeostasis and antibody responses. Eur J Immunol. 2011;41:787–97.
Article
CAS
PubMed
Google Scholar
Huard B, Schneider P, Mauri D, Tschopp J, French L. T cell costimulation by the TNF ligand BAFF. J Immunol. 2001;167:6225–31.
Article
CAS
PubMed
Google Scholar
Ng L, Sutherland A, Newton R, Qian F, Cachero T, Scott M, et al. B cell-activating factor belonging to the TNF family (BAFF)-R is the principal BAFF receptor facilitating BAFF costimulation of circulating T and B cells. J Immunol. 2004;173:807–17.
Article
CAS
PubMed
Google Scholar
Sutherland A, Ng L, Fletcher C, Shum B, Newton R, Grey S, et al. BAFF augments certain Th1-associated inflammatory responses. J Immunol. 2005;174:5537–44.
Article
CAS
PubMed
Google Scholar
Zhou X, Xia Z, Lan Q, Wang J, Su W, Han Y, et al. BAFF promotes Th17 cells and aggravates experimental autoimmune encephalomyelitis. PLoS One. 2011;6, e23629.
Article
PubMed Central
CAS
PubMed
Google Scholar